HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The...
Hence then, the article about cadonilimab pd 1 ctla 4 receives fda clearance for global phase iii first line gastric cancer trial versus nivolumab was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab )
Also on site :
- Elon Musk’s Exes Reveal His ‘Assembly Line’ Approach to Having Kids in New Documentary: ‘Somebody on Elon’s Side Referred to Us as “the Breeders”’
- Carson Kressley Just Mic-Dropped Vicki Gunvalson’s ‘RHOC’ Motor Boating Outfit and the Internet Can’t Stop Screaming
- Brad Bird’s ‘Ray Gunn,’ ‘Toy Story 5’ and Roger Deakins Lead View Conference Lineup as AI Debate Takes Center Stage